drugset / Trial / NCT00797784

The Safety and Efficacy of Etanercept (Enbrel®) for the Treatment of Discoid Lupus Erythematosus

NCT00797784

Phase 2 Unknown 20 enrolled Florida Academic Dermatology Centers
NaSingle-groupOpen-labelTreatment

Summary

A 20 week study to assess the safety and efficacy of etanercept(Enbrel®)for the treatment of Discoid Lupus Erythematosus

Timeline

Start
2008-10
Primary completion
2011-04
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 50 mg Subcutaneous